pal-1 Antibody
Description
Molecular Identity and Historical Context
-
Vimentin Hypothesis: Early work suggested PAL-E binds to a modified or complexed form of vimentin, detectable only under non-reducing conditions . Immunoprecipitation studies revealed a dominant 120-kDa band under non-reduced conditions, shifting to 55 kDa upon reduction .
-
PV-1 Validation: Transfection experiments confirmed PAL-E reactivity with PV-1 but not neuropilin-1 (NRP-1) . Co-immunoprecipitation demonstrated PV-1 forms complexes with NRP-1, explaining overlapping staining patterns .
Table 1: PAL-E Antigen Identification Timeline
Biochemical and Functional Characteristics
PAL-E exhibits unique biochemical properties:
-
Reduction Sensitivity: PAL-E antigen is undetectable in immunoblots under reduced conditions, complicating early identification .
-
Molecular Weight: Under non-reduced conditions, the antigen appears as a 120-kDa band, while reduction yields a 55-kDa fragment .
-
Tissue Specificity: Labels blood capillaries, small veins, and tumor vasculature but excludes arterial, brain, and lymphatic endothelia .
Applications in Research and Diagnostics
PAL-E is widely used to:
-
Differentiate Vascular Endothelia: Distinguishes blood vessels (PAL-E+) from lymphatic vessels (PAL-E−) in skin and tumor tissues .
-
Study Tumor Angiogenesis: Marks proliferating tumor vasculature, aiding in cancer research .
-
Investigate Vascular Permeability: PV-1’s role in endothelial fenestrations links PAL-E to studies on vascular leakage .
Table 2: Key Applications of PAL-E Antibody
| Application | Target Tissue | Utility |
|---|---|---|
| Vascular Mapping | Skin, lymph nodes | Identifies blood vs. lymphatic endothelia |
| Tumor Vasculature Analysis | Melanoma, carcinomas | Highlights angiogenic hotspots |
| Developmental Biology | Embryonic tissues | Tracks vascular maturation |
Controversies and Resolutions
The initial misidentification of PAL-E’s target as vimentin stemmed from technical limitations, including antigen sensitivity to reduction and cross-reactivity with intermediate filament proteins . Subsequent studies using molecular cloning and transfected cells clarified PV-1 as the definitive antigen .
Recent Advances
While PAL-E remains a staple in vascular biology, newer antibodies targeting PV-1 with broader compatibility (e.g., paraffin-embedded sections) have emerged, enhancing diagnostic utility . Ongoing research explores PV-1’s role in endothelial signaling and its potential as a therapeutic target in cancer and inflammatory diseases .
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- A developmental switch in the translational control of *C. elegans* PAL-1 is mediated by the STAR/Maxi-KH domain protein GLD-1. PMID: 15201219
- PAL-1 specifies the identity and maintains the development of the multipotent C blastomere lineage in the *C. elegans* embryo. PMID: 15772128
Q&A
Basic Research Questions
What experimental controls are essential when using PAL-1 antibodies in immunoassays?
-
Positive controls: Use tissues or cell lines with confirmed PAL/PAM expression (e.g., neuronal or cardiac tissues, as PAL is linked to nervous system development ).
-
Negative controls: Include tissues lacking PAL expression (e.g., muscle or bone marrow) and isotype-matched antibodies to rule out nonspecific binding .
-
Technical controls: Validate secondary antibody compatibility (e.g., anti-host species conjugates) and include buffer-only lanes in Western blots .
How should PAL-1 antibodies be stored and diluted to maintain functionality?
-
Storage: Aliquot antibodies into ≥10 µl volumes to minimize evaporation and adsorption loss. Store at -20°C or -80°C as specified .
-
Dilution guidelines:
How do researchers validate PAL-1 antibody specificity in novel models?
-
Knockout validation: Compare staining in wild-type vs. PAL/PAM knockout tissues.
-
Competitive assays: Pre-incubate antibodies with recombinant PAL protein to confirm signal reduction .
-
Orthogonal methods: Cross-validate with mass spectrometry or mRNA expression data .
Advanced Research Questions
How can epitope mapping resolve contradictions in PAL-1 antibody performance across studies?
-
Structural analysis: Use computational tools (e.g., FoldX, I-TASSER) to model PAL’s 3D structure and predict antibody binding regions .
-
Alanine scanning: Systematically replace residues (e.g., MKS257-259 in PAL) to identify critical epitopes. Variants like Pal v3 (280-282 DKP→GGA) showed reduced antibody cross-reactivity while enhancing lytic activity .
-
Cross-neutralization assays: Test antibody binding against engineered PAL variants (e.g., Pal v1, v3, v9) to map immunodominant regions .
What methodologies optimize PAL-1 antibody utility in in vivo immunogenicity studies?
-
Serum profiling: Monitor IgG kinetics post-administration. For example, Pal v1 induced sustained IgG levels for 7 weeks, while Pal v9 showed rapid decline .
-
Functional neutralization assays: Compare lytic activity of PAL variants in serum-containing vs. serum-free conditions. Pal v3 retained 85% activity in 15% murine serum vs. 40% for wild-type PAL .
-
Dose-response modeling: Use linear regression or one-phase association models to quantify lytic activity under varying antibody concentrations .
How do researchers reconcile conflicting data on PAL-1 antibody cross-reactivity?
-
Epitope binning: Group antibodies by competitive binding patterns. For example, antibodies targeting PAL’s C-terminal region (residues 257-282) show higher cross-neutralization than those binding the N-terminal catalytic domain .
-
ΔΔG analysis: Calculate folding energy changes after epitope modifications. Substitutions with ΔΔG < 2 kcal/mol (e.g., MKS→TFG) minimized structural destabilization while reducing immunogenicity .
-
Multiplexed validation: Combine SPR, ELISA, and functional lytic assays to resolve discrepancies between binding affinity and biological activity .
What strategies enhance PAL-1 antibody specificity for therapeutic applications?
-
Charge-swap mutagenesis: Replace charged residues (e.g., D280→G280) to disrupt ionic interactions with off-target proteins .
-
Domain shielding: Fuse PAL with albumin-binding domains to sterically block nonspecific antibody interactions .
-
High-resolution screening: Use cryo-EM or hydrogen-deuterium exchange mass spectrometry to refine epitope boundaries .
